Abstract: A microscope module for imaging a sample includes at least one illumination objective for producing an illumination beam along an illumination beam path arranged to illuminate lower surfaces of the sample and at least one detection objective having a detection path. The detection path is at an angle to the illumination beam path.

Abstract: A microscope module for imaging a sample includes at least one illumination objective for producing an illumination beam along an illumination beam path) arranged to illuminate lower surfaces of the sample and at least one detection objective having a detection path. The detection path is at an angle to the illumination beam path.

Abstract: A microscope module (300) for imaging a sample (270) includes at least one illumination objective (210) for producing an illumination beam along an illumination beam path (215) arranged to illuminate lower surfaces of the sample (270) and at least one detection objective (220) having a detection path (225). The detection path (225) is at an angle to the illumination beam path (215).

Abstract: A microscope module (300) for imaging a sample (270) is disclosed. The microscope module (300) includes at least one illumination objective (210) for producing an illumination beam along an illumination beam path (215) arranged to illuminate lower surface of the sample (270) and at least one detection objective (220) having a detection path (225). The detection path (225) is at an angle to the illumination beam path (215).

Abstract: A microscope module (300) for imaging a sample (270) is disclosed. The microscope module (300) includes at least one illumination objective (210) for producing an illumination beam along an illumination beam path (215) arranged to illuminate lower surface of the sample (270) and at least one detection objective (220) having a detection path (225). The detection path (225) is at an angle to the illumination beam path (215).

Abstract: The present invention describes methods for determining the risk that a breast precursor lesion will progress to invasive breast cancer and/or the risk of recurrent non-invasive disease in a patient, comprising detecting the presence and/or level of PAPA and/or PAPPA functional activity in a breast tissue sample obtained from the patient, wherein if PAPPA is not present, or is present at a reduced amount compared to a control, the is the risk of progression to invasive cancer and/or the risk or recurrent disease. The present invention also enables the chemosensitisation of mitotically delayed breast cancer cells to anti-proliferative agents, preferably anti-mitotic agents, by restoring normal progression through mitosis. In this embodiment a first drug is applied to release breast cancer cells from the mitotic block and, sequentially, a second drug affecting proliferating cells is administered for cancer cell killing.

Abstract: A microscope module (300) for imaging a sample (270) is disclosed. The microscope module (300) comprises at least one illumination objective (210) for producing an illumination beam along an illumination beam path (215) arranged to illuminate lower surface of the sample (270) and at least one detection objective (220) having a detection path (225). The detection path (225) is at an angle to the illumination beam path (215).

Abstract: The present invention relates to liposome arrays, devices comprising said liposome arrays, the uses of said liposome arrays as well as methods of producing said liposome arrays.

Abstract: The present invention describes methods for determining the risk that a breast precursor lesion will progress to invasive breast cancer and/or the risk of recurrent non-invasive disease in a patient, comprising detecting the presence and/or level of PAPPA and/or PAPPA functional activity in a breast tissue sample obtained from the patient, wherein if PAPPA is not present, or is present at a reduced amount compared to a control, there is the risk of progression to invasive cancer and/or the risk or recurrent disease. The present invention also enables the chemosensitisation of mitotically delayed breast cancer cells to anti-proliferative agents, preferably anti-mitotic agents, by restoring normal progression through mitosis. In this embodiment a first drug is applied to release breast cancer cells from the mitotic block and, sequentially, a second drug affecting proliferating cells is administered for cancer cell killing.